Literature DB >> 32749857

Long Noncoding RNA XIST Acts as a ceRNA of miR-362-5p to Suppress Breast Cancer Progression.

Baoyin Liu1, Chengyu Luo1, Hua Lin2, Xiaoxin Ji2, Enyu Zhang2, Xin Li2.   

Abstract

Background: Long noncoding RNAs (lncRNAs) X inactivate-specific transcripts (XIST) have been found to be dysregulated in breast cancer (BC). Nevertheless, the influence and mechanism of XIST on BC progression remain largely undefined.
Methods: The expression levels of XIST, miR-362-5p, and ubiquitin-associated protein 1 (UBAP1) mRNA were detected by quantitative real-time polymerase chain reaction. Cell proliferation, apoptosis, migration, and invasion abilities were determined using MTT assay, flow cytometry, and transwell assay, respectively. Targeted relationship between miR-362-5p and XIST or UBAP1 was validated by the dual-luciferase reporter assay. Western blot was performed to evaluate UBAP1 protein level. Xenograft mice model was established for the investigation of XIST in tumor growth.
Results: The authors' data indicated that XIST and UBAP1 were downregulated in BC tissues and cells. XIST overexpression weakened BC cell proliferation, migration, invasion, and facilitated the apoptosis, and XIST silencing exerted opposite effect. Mechanistically, XIST directly interacted with miR-362-5p and miR-362-5p mediated the regulatory effects of XIST overexpression on BC cell malignant behaviors. UBAP1 was a direct target of miR-362-5p. MiR-362-5p exerted its regulatory effects on BC cell behaviors by UBAP1. Moreover, XIST modulated UBAP1 expression through acting a competing endogenous RNA of miR-362-5p. XIST overexpression mediated antiproliferation, antimigration, anti-invasion, and proapoptosis effects were abated by the restored expression of UBAP1 in BC cells. Furthermore, the upregulation of XIST hindered tumor growth in vivo.
Conclusion: The current study suggested that XIST overexpression hampered BC cell progression in vitro and in vivo at least partially by targeting the miR-362-5p/UBAP1 axis, illuminating XIST as a promising therapeutic agent for BC management.

Entities:  

Keywords:  BC progression; UBAP1; XIST; ceRNA; miR-362-5p

Mesh:

Substances:

Year:  2020        PMID: 32749857     DOI: 10.1089/cbr.2019.3481

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  7 in total

1.  XIST sponges miR-320d to promote chordoma progression by regulating ARF6.

Authors:  Yonggang Wang; Zhouzhou Tang; Weichun Guo
Journal:  J Bone Oncol       Date:  2022-07-16       Impact factor: 4.491

2.  A novel mutation in the UBAP1 gene causing hereditary spastic paraplegia: A case report and overview of the genotype-phenotype correlation.

Authors:  Peiqiang Li; Xiande Huang; Senmao Chai; Dalin Zhu; Huirong Huang; Fengdie Ma; Shasha Zhang; Xiaodong Xie
Journal:  Front Genet       Date:  2022-07-14       Impact factor: 4.772

Review 3.  Long noncoding RNA XIST: Mechanisms for X chromosome inactivation, roles in sex-biased diseases, and therapeutic opportunities.

Authors:  Jianjian Li; Zhe Ming; Liuyi Yang; Tingxuan Wang; Gaowen Liu; Qing Ma
Journal:  Genes Dis       Date:  2022-04-29

4.  Pan-cancer analysis of LncRNA XIST and its potential mechanisms in human cancers.

Authors:  Wei Han; Chun-Tao Shi; Jun Ma; Hua Chen; Qi-Xiang Shao; Xiao-Jiao Gao; Ying Zhou; Jing-Feng Gu; Hao-Nan Wang
Journal:  Heliyon       Date:  2022-09-28

Review 5.  X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis.

Authors:  Soudeh Ghafouri-Fard; Sepideh Dashti; Molood Farsi; Mohammad Taheri; Seyed Ali Mousavinejad
Journal:  Front Cell Dev Biol       Date:  2021-06-11

Review 6.  Biological Function of Long Non-coding RNA (LncRNA) Xist.

Authors:  Wenlun Wang; Lu Min; Xinyuan Qiu; Xiaomin Wu; Chuanyang Liu; Jiaxin Ma; Dongyi Zhang; Lingyun Zhu
Journal:  Front Cell Dev Biol       Date:  2021-06-10

7.  Long noncoding RNA ZBED3-AS1 restrains breast cancer progression by targeting the microRNA-513a-5p/KLF6 axis.

Authors:  Aiqin Fu; Ze Yu; Enning Zhang; Jijie Song
Journal:  Thorac Cancer       Date:  2021-08-24       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.